NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax's EMA Scientific Advice for GEO-MVA Phase 3 Trial
TL;DR
GeoVax's EMA alignment accelerates GEO-MVA's Phase 3 trial, potentially creating a competitive advantage in the Mpox/smallpox vaccine market by 2026.
EMA's Scientific Advice confirms GeoVax can proceed directly to a single Phase 3 immunobridging study against Imvanex, streamlining the regulatory pathway to commercialization.
GEO-MVA's development strengthens global vaccine supply diversification, enhancing preparedness against Mpox and smallpox threats for better public health protection worldwide.
GeoVax's MVA-based vaccine candidate skips Phase 1/2 trials, moving straight to Phase 3 in 2026 following EMA's regulatory alignment on trial design.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs announced it received formal Scientific Advice from the European Medicines Agency (EMA) confirming regulatory alignment on the proposed pivotal Phase 3 immunobridging trial design for GEO-MVA, its Modified Vaccinia Ankara (MVA)-based vaccine candidate for preventing Mpox and smallpox.
This formal Scientific Advice represents a major regulatory milestone that de-risks GeoVax's regulatory path in Europe, enables acceleration toward Phase 3 initiation, and moves GEO-MVA from a conceptual regulatory pathway to a clearly defined and executable development plan toward commercialization.
EMA confirmed that non-inferiority immunogenicity endpoints are acceptable to support a future Marketing Authorization Application (MAA), that GeoVax's proposed clinical safety database is sufficient to support registration (assuming successful trial outcomes), and that the company can proceed directly to Phase 3 without additional Phase 1 or 2 studies.
The Phase 3 program is currently projected to begin in the second half of 2026.
The trial will be a single, pivotal Phase 3 immunobridging study comparing GEO-MVA against the approved MVA vaccine Imvanex®, evaluating non-inferiority immunogenicity endpoints.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that this 'represents a pivotal step forward for GEO-MVA and meaningfully de-risks our regulatory path in Europe' and positions the company to move efficiently toward a single, registrational Phase 3 study.
This development strengthens GEO-MVA's potential role in expanding global Mpox and smallpox vaccine supply beyond the current single-supplier paradigm, supporting global health authorities' emphasis on preparedness, resilience, and diversification of vaccine supply.
GEO-MVA is GeoVax's Modified Vaccinia Ankara (MVA)-based vaccine candidate being developed for the prevention of Mpox and smallpox, leveraging the well-characterized MVA platform to support both civilian public health needs and broader preparedness objectives.
This receipt of formal Scientific Advice follows GeoVax's previous announcement of favorable preliminary EMA guidance announced in June 2025, marking the transition from regulatory alignment to regulatory execution.
Curated from NewMediaWire
